Alpelisib: as the comparator
3 studies: what is tested is compared with it. Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.
- Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast CancerRecruitingNCT06837792Phase 2Report a problem
- A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyRecruitingNCT05646862Phase 3Report a problem
- Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)Active, not recruitingNCT05501886Phase 3Report a problem